Jeanelle Tsai, BA, (Jeanellea_tsai@dfci.harvard.edu) works on identifying genes that cause drug resistance in EGFR-mutant NSCLCs using a genome-wide CRISPR activation screening system. She is assessing the efficacy of targeting those genes in vitro with the goal of eliminating minimal residual disease (MRD).
Caitlyn Weston, BA, (Caitlynn_Weston@dfci.harvard.edu) works on investigating the effects of various RTKi combination treatments in an effort to overcome and prevent acquired resistance to EGFR-targeted therapies in EGFR-mutant NSCLC. She also works on the Cell Establishment Team to process and establish patient and PDX models for in-lab use
Soumya Malhotra, BA, MS (firstname.lastname@example.org) works on EGFR, ALK, KRAS and ROS mutant NSCLC cell lines with a goal to identify drug therapies targeting persister cells. Soumya also works with patient samples and PDX to develop in vitro 2D and 3D NSCLC models.